Literature DB >> 17197880

Postexposure prophylaxis after sexual exposure to HIV.

Michelle E Roland1.   

Abstract

PURPOSE OF REVIEW: HIV postexposure prophylaxis is often recommended following potential sexual exposure to HIV. Recent data address the effectiveness of postexposure prophylaxis and prevention counseling, cost-effectiveness, antiretroviral options, challenges with nonoccupational postexposure prophylaxis among adolescents and children and following sexual assault in high HIV prevalence areas, and a successful program in Amsterdam. RECENT
FINDINGS: Postexposure prophylaxis is not completely protective. Seroconversion may result from antiretroviral failure or from ongoing exposures. Postexposure prophylaxis associated risk reduction counseling results in reductions in subsequent risk behavior. Programs that target outreach and limit prescriptions to those with exposure sources who are at risk of being HIV infected are cost-effective. Less restrictive guidelines result in more prescriptions for low-risk exposures; this practice is not cost-effective. The ideal antiretrovirals for postexposure prophylaxis use have not been established. Tenofovir has several attractive properties. Developing systems to support the effective delivery of postexposure prophylaxis among children and adolescents and following sexual assault in high HIV prevalence, resource limited settings is challenging.
SUMMARY: Numerous national and international guidelines recommend postexposure prophylaxis following potential sexual exposure to HIV. Maximizing adherence and minimizing subsequent HIV exposures will be critical to enhancing the effectiveness of this HIV prevention intervention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17197880     DOI: 10.1097/QCO.0b013e328012c5e0

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  8 in total

1.  Uptake to HIV post-exposure prophylaxis in Haiti: opportunities to align sexual violence, HIV PEP and mental health.

Authors:  Linda Marc; Jean-Guy Honoré; Patrick Néjuste; Monica Setaruddin; Nika-Nola Lamothe; Gabriel Thimothé; Jean-Ronald Cornely
Journal:  Am J Reprod Immunol       Date:  2012-12-28       Impact factor: 3.886

Review 2.  Prevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers).

Authors:  Susan E Beekmann; David K Henderson
Journal:  Infect Dis Clin North Am       Date:  2014-10-05       Impact factor: 5.982

Review 3.  The essentials of HIV: a review for nurses.

Authors:  Andrew E Petroll; C Bradley Hare; Steven D Pinkerton
Journal:  J Infus Nurs       Date:  2008 Jul-Aug

Review 4.  AIDS vaccines and preexposure prophylaxis: is synergy possible?

Authors:  Jean-Louis Excler; Wasima Rida; Frances Priddy; Jill Gilmour; Adrian B McDermott; Anatoli Kamali; Omu Anzala; Gaudensia Mutua; Eduard J Sanders; Wayne Koff; Seth Berkley; Patricia Fast
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-16       Impact factor: 2.205

5.  Sustainability of an HIV PEP Program for Sexual Assault Survivors: "Lessons Learned" from Health Care Providers.

Authors:  Janice Du Mont; Sheila Macdonald; Terri Myhr; Mona R Loutfy
Journal:  Open AIDS J       Date:  2011-11-30

6.  Trends in condom use and risk behaviours after sexual exposure to HIV: a seven-year observational study.

Authors:  Enrique Casalino; Christophe Choquet; Agathe Leleu; Romain Hellmann; Mathias Wargon; Gaelle Juillien; Yazdan Yazdanpanah; Elisabeth Bouvet
Journal:  PLoS One       Date:  2014-08-26       Impact factor: 3.240

7.  A comparison of intimate partner and other sexual assault survivors' use of different types of specialized hospital-based violence services.

Authors:  Janice Du Mont; Maryam Woldeyohannes; Sheila Macdonald; Daisy Kosa; Linda Turner
Journal:  BMC Womens Health       Date:  2017-08-07       Impact factor: 2.809

8.  Prevention of the sexual transmission of HIV-1: preparing for success.

Authors:  Myron S Cohen; Pontiano Kaleebu; Thomas Coates
Journal:  J Int AIDS Soc       Date:  2008-10-01       Impact factor: 5.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.